Fundz

Who to call at BridgeBio, and when

Fundz watches for the moments BridgeBio starts buying, and tells you who to reach.

  • An alert the day BridgeBio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at BridgeBio, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

LaunchBridgeBio Pharma, Inc. launches BEYONTTRA™ (acoramidis), a new treatment for transthyretin amyloidosis approved by the European Commission.

Feb 11, 2025
Palo AltoBiotechnologyHealth CareTherapeutics

Product Description

BridgeBio Pharma, Inc. announces the European Commission's grant of marketing authorization for BEYONTTRA™, an oral medication for treating wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy. The approval is based on significant clinical trial results showing benefits in cardiovascular outcomes.

Company Information

Company

BridgeBio

Location

Palo Alto, California, United States

About

BridgeBio Oncology Therapeutics (BBOT) has launched with a $200m private financing round, aiming to expedite the development of the company’s precision oncology pipeline and focusing on new cancer treatments.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment BridgeBio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Damian hidden

hidden
Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for BridgeBio's next move

Learn about Strategic plan

Product Launch Insights

What this usually means
Market expansion signals
New product launches often coincide with market expansion initiatives

BridgeBio shipped something new. Fundz reads product launches, trademark filings and hiring together.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.